Novo Nordisk (NYSE: NVO) functions as a dividend-paying stock, distributing cash dividends semi-annually to its shareholders based on its robust financial performance within the global healthcare and pharmaceutical sector. The company has a long-standing history of consistent dividend distributions supported by strong earnings growth from its market-leading diabetes and obesity care treatments. Income-oriented and growth-and-income investors frequently include it in their portfolios to capture both capital appreciation and reliable cash returns.